share_log

Why Baudax Bio Shares Trading Higher Today

Why Baudax Bio Shares Trading Higher Today

為什麼鮑達斯生物股票今天交易走高
Benzinga Real-time News ·  2023/01/25 00:41
  • Baudax Bio Inc (NASDAQ:BXRX) announced the outcome of its first interim analysis in a Phase 2 trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery.
  • The trial evaluates three doses of BX1000 to a standard dose of rocuronium and expects to enroll 80 adult patients undergoing elective surgery utilizing total intravenous anesthesia.
  • Additionally, the trial evaluates the safety and tolerability profile of BX1000 and rocuronium in this patient population.
  • The pre-planned interim analysis evaluated the intubating conditions for each patient after administering the study drug in a blinded fashion.
  • All 20 patients were observed to have met the criteria for Good or Excellent intubating conditions at 60 seconds. Nineteen of the subjects were successfully intubated following the assessment at 60 seconds, and the remaining subject followed the assessment at 90 seconds.
  • Study treatments were generally well tolerated, with no severe or serious adverse events.
  • The company plans to complete enrollment in the study in Q1 and share the topline results for the study in April 2023.
  • Price Action: BXRX shares are up 39.40% at $4.39 on the last check Tuesday.
  • 鮑達斯生物公司 （NASDAQ：BXRX）宣布了在接受選擇性手術的患者中的 BX1000 用於神經肌肉阻滯（NMB）的 2 期試驗中首次中期分析的結果。
  • 該試驗將三劑 BX1000 評估為標準劑量的羅庫洛尼銨，並預計將對 80 名使用全靜脈麻醉進行選擇性手術的成年患者進行投保。
  • 此外，該試驗還評估了 BX1000 和羅庫洛銨在此患者群體中的安全性和耐受性。
  • 預先計劃的中期分析以盲目的方式評估了每個患者在使用研究藥物後的插管狀況。
  • 觀察到所有 20 名患者在 60 秒內都符合「良好」或「優異」插管狀況的標準。其中 19 名受試者在評估後在 60 秒內成功插入，其餘受試者則在 90 秒內完成評估。
  • 研究治療通常耐受性良好，沒有嚴重或嚴重的不良事件。
  • 該公司計劃在第一季度完成該研究的註冊，並分享 2023 年 4 月該研究的結果。
  • 價格行動： BXRX 的股票在上次檢查週二上漲了 39.40％，價格為 4.39 美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論